Yuji Yamada

Citigroup Global Markets Japan, Inc. (CGM-JP) is a wholly-owned broker/dealer subsidiary of Citigroup Japan Holdings GK, ultimately held by Citigroup, Inc. (NYSE: C) in the US. Previously known as Nikko Citigroup Ltd., the firm was founded in 1999 as a joint venture between US-based Citigroup and Nikko Securities, based in Japan. Headquartered in Tokyo, CGM-JP provides brokerage services to governmental institutions, financial institutions, multinational corporations and institutional investors. Their sales and trading, distribution and research capabilities span a broad range of asset classes, currencies, sectors and products including equities, commodities, credit, futures, foreign exchange (FX), emerging markets, G10 rates, municipals, prime finance and securitized markets.

Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa.

Megakaryon Corp. operates as an pluripotent stem cells research laboratory. It produce platelets and red blood cells from iPS cell lines, and to develop blood products that do not depend on blood donations. The firm specializes in development of technologies to produce and store induced pluripotent stem cell derived human T cells. Megakaryon was founded by Genjiro Miwa on September 9, 2011 and is headquartered in Kyoto, Japan.

Quantum Biosystems, Inc. is a holding company that develops single-molecule DNA sequencers. It develops and commercializes sequencers based on quantum mechanics. The company was founded by Toshihiko Honkura and Masateru Taniguchi on January 7, 2013 and is headquartered in Osaka, Japan.

Agra Corp. develops and sells data management and analysis software. It specializes in data integration and data mapping solutions. It also offers visualization and virtual data consolidation services. The company was founded by Hiroshi Tange in March 2008 and is headquartered in Tokyo, Japan.

CellGenTech, Inc. engages in the research and development of drugs for new gene therapy and regenerative medicine. It offers adipocyte-based medicine, technology for the development of gene/cell therapies. It also provides protein supplemental therapy solutions in the areas of hereditary diseases; orphan diseases; intractable diseases, such as lysosome and hemophilia; diabetics; arteriosclerotic diseases, and cancer or degenerative neuropathies. The company was founded by Masayuki Aso on October 20, 2003 and is headquartered in Chiba, Japan.

SCOHIA PHARMA, Inc. is a drug discovery venture that focuses on lifestyle-related diseases. The company is based in Fujisawa, Japan. The Japanese company has a strong development pipeline and an experienced R & D team that specializes in drug discovery, including compound creation, drug efficacy evaluation, and clinical development. The CEO of the company is Masanori Watanabe.

Rin Institute, Inc. is a company based in Tokyo, Japan that was founded in 2016 by Kentaro Yoshimatsu. The Japanese company's website simply states that it is "just another WordPress site."

Watervein Partners KK (Watervein Partners) is an independent venture capital firm headquartered in Tokyo, Japan. The firm was founded in 2002 by Kuroishi Masafumi.